............................
2015
2014
2013
Archive
............................
Portfolio News
............................
New Leaf News
............................
|
Chimerix Announces Pricing of
Initial Public Offering
RESEARCH TRIANGLE PARK, N.C., April 11, 2013 (GLOBE NEWSWIRE) --
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing
novel, oral antivirals in areas of high unmet medical need, announced
today the pricing of its initial public offering of 7,320,000 shares of
its common stock at a price to the public of $14.00 per share. The
shares of Chimerix's common stock are scheduled to begin trading on the
NASDAQ Global Market under the symbol "CMRX" on April 11, 2013. All of
the shares of common stock are being offered by Chimerix. In addition,
Chimerix has granted the underwriters a 30-day option to purchase up to
an additional 1,098,000 shares of common stock to cover over-allotments,
if any. The offering is expected to close on April 16, 2013, subject to
customary closing conditions.
Morgan Stanley and Cowen and Company are acting as joint book-running
managers for the offering. William Blair and Lazard Capital Markets are
acting as co-managers.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on April 10, 2013.
The offering will be made only by means of a prospectus. Copies of the
prospectus relating to the offering may be obtained from: Morgan Stanley
& Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor,
New York, NY 10014, or by calling toll free 1-866-718-1649 or emailing
at prospectus@morganstanley.com; or Cowen and Company, LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY
11717, Attn: Prospectus Department, by calling (631) 274-2806, or faxing
(631) 254-7140.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
About Chimerix and CMX001
Chimerix is committed to the discovery, development and
commercialization of novel, oral antiviral therapeutics designed to
transform patient care in areas of high unmet medical need. The
Company's proprietary lipid technology has given rise to two
clinical-stage lipid acyclic nucleoside phosphonates, CMX001 and CMX157,
which have demonstrated the potential for enhanced activity and safety
in convenient, orally administered dosing regimens.
Chimerix's lead product candidate, CMX001, is a broad spectrum, oral
nucleotide analog lipid-conjugate that blocks replication of
double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV),
adenovirus (AdV), BK virus and herpes simplex virus. CMX001 has
completed Phase 2 clinical development for the prevention of CMV in
hematopoietic stem cell transplant (HSCT) recipients. Chimerix is also
conducting a Phase 2 study in HSCT recipients which is evaluating CMX001
as a preemptive therapy for AdV disease, an often-fatal infection which
has no approved therapies. Since 2009, Chimerix has made CMX001
available under expanded access regulations to over 80 transplant
centers worldwide for the treatment of over 430 patients with
life-threatening dsDNA viral infections. Chimerix anticipates initiating
SUPPRESS, its Phase 3 study of CMX001 for the prevention of CMV
infection in adults undergoing HSCT, in 2013.
Chimerix is also developing CMX001 as a potential medical countermeasure
against smallpox under a contract from the Biomedical Advanced Research
and Development Authority (BARDA).
Chimerix's second product candidate, CMX157, an oral nucleotide analog
lipid-conjugate in Phase 1 development for the treatment of HIV
infection, was licensed to Merck in July 2012.
Chimerix Contacts
Rebecca Heath, 919.972.7124
Elizabeth Kelly, 919.972.7109
Media Contact
Tony Plohoros
908.940.0135
tplohoros @6degreespr.com
Investor Contact
Lillian Stern
212.362.1200
lilian @sternir.com |